Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 40.00
Ask: 44.00
Change: 0.00 (0.00%)
Spread: 4.00 (10.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 40.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of senior advisers

22 Oct 2019 07:00

RNS Number : 6114Q
Frontier IP Group plc
22 October 2019
 

RNS REACH

AIM: FIPP

22 October 2019

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Frontier IP appoints senior advisers to step up industry engagement

 

 

Frontier IP, a specialist in commercialising university intellectual property, today announces the appointment of John Price and Air Vice-Marshal Gary Waterfall CBE as specialist advisers to deepen and expand the Group and its portfolio companies' industrial partnerships.

 

John and Gary will provide specialist expertise, insight and advice across the food and agriculture, and defence industries respectively, to support Frontier IP and its portfolio companies. The roles are part time and they will not sit on the Group's board of directors.

 

John has been appointed as Senior Food and Agritech Adviser. He spent 25 years working for Mars, Incorporated ("Mars"), the global food and petcare group, where he rose to become Vice-President Operations Europe. He subsequently became chairman of Mars' pension fund trustees.

 

Gary has been appointed Senior Defence Adviser. He served for 34 years in the Royal Air Force, including flying Harriers and serving for three years with the Royal Air Force Acrobatic Team, The Red Arrows. His roles included commanding the Royal Air Force's Air Combat Group (No 1 Group) and service as the UK's National Air Defence Commander. His final role before retirement was as Chief of Staff at The Permanent Joint Headquarters at Northwood, where he was responsible for planning and executing joint operations involving all three services around the world. He is also a fellow of the Royal Aeronautical Society.

 

These appointments reflect the growing maturity of the Group's business and the technologies under development throughout the portfolio, which has resulted in increasing interest and traction from industry.

 

Portfolio companies collaborating closely with industry include Fieldwork Robotics, Molendotech, Nandi Proteins, Pulsiv Solar and The Vaccine Group. Industry and sector collaborators announced to date include Bosch, Devro, G's Group, Hall Hunter Partnership, Palintest, and the US Defense Advanced Project Research Agency.

 

Commenting on the appointments, John Price said: "I'm delighted to be joining Frontier IP at such an exciting time of innovation in the food and agritech industries, driven by changing consumer tastes and rapid advances in technology. There is strong potential in the Group's portfolio companies to take advantage of these trends."

 

Air Vice-Marshal Gary Waterfall said: "It is a real honour to join Frontier IP at such an important period. Already I can see clear synergies and potential utility for many of Frontier IP's current collaborative partnerships across wide swathes of UK Defence as it continues to be a force for good employed on operations around the globe."

 

Neil Crabb, chief executive officer of Frontier IP, said: "Industry engagement is a central part of what we do. It allows us to validate technology, understand how best to scale up, and ensures we are meeting real-world needs or demands. The vast experience of John and Gary and the support they can provide will help to significantly strengthen this aspect of our business."

 

ENQUIRIES

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

M: 07464 546 025

Group website: www.frontierip.co.uk

 

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers

 

ABout frontier IP

Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAPGGCCUUPBGAG
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.